Clinical Scorecard: Clinical Trial Update March 2026
At a Glance
Category
Detail
Condition
Key Mechanisms
Evaluation of safety, tolerability, and efficacy of various treatments including intravitreal injections, oral medications, and other innovative therapies.
Target Population
Care Setting
Key Highlights
Multiple Phase 1 and 2 studies evaluating new treatments for Geographic Atrophy (GA) associated with AMD, with preliminary efficacy results indicating potential benefits.
Studies include various administration routes such as intravitreal injections and oral medications, with some showing promising early outcomes.
Focus on safety, tolerability, and efficacy across diverse patient populations, with specific attention to demographic variations.
Guideline-Based Recommendations
Diagnosis
Management
Consider participation in clinical trials for patients with advanced AMD or GA, particularly those who have exhausted standard treatment options.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Emerging therapies include intravitreal injections and SGLT2 inhibitors, with ongoing studies assessing their long-term efficacy.
Clinical Best Practices
Engage patients in discussions about the potential benefits and risks of participating in clinical trials, including long-term follow-up care.
Monitor patients closely for adverse effects during and after treatment in clinical trials, ensuring a structured follow-up plan.
